Zartra
Withdrawn
This medicine's authorisation has been withdrawn
imiquimod
MedicineHumanWithdrawn
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for Zartra has been withdrawn at the request of the marketing authorisation holder.
Product information
11/06/2002
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Zartra
- Active substance
- imiquimod
- International non-proprietary name (INN) or common name
- imiquimod
- Therapeutic area (MeSH)
- Condylomata Acuminata
- Anatomical therapeutic chemical (ATC) code
- L03AX
Pharmacotherapeutic group
ImmunostimulantsTherapeutic indication
Imiquimod cream is indicated for the topical treatment of external genital and perianal warts (condyloma acuminata) in adult patients.
This page was last updated on